FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
|
Comparision between Hemant Surgical Industries IPO and Remus Pharmaceuticals IPO.
Hemant Surgical Industries IPO is a SME Book Built Issue IPO proposed to list at BSE SME while Remus Pharmaceuticals IPO is a SME Book Built Issue proposed to list at NSE SME.
Hemant Surgical Industries IPO | Remus Pharmaceuticals IPO | |
---|---|---|
Logo | ||
Issue Category | SME | SME |
Issue Type | IPO | IPO |
Process Type | Book Built Issue | Book Built Issue |
Listing At | BSE SME | NSE SME |
Lead Managers | Hem Securities Limited | Beeline Capital Advisors Pvt Ltd |
Registrar | Bigshare Services Pvt Ltd | Link Intime India Private Ltd |
Market Maker | Hem Finlease Private Limited | Sunflower Broking Private Limited |
DRHP | DRHP | DRHP |
RHP | RHP | RHP |
Anchor Investor | Anchor Investor | Anchor Investor |
IPO Allotment URL | IPO Allotment URL | IPO Allotment URL |
The total issue size of Hemant Surgical Industries IPO is up to ₹24.84 Cr whereas the issue size of the Remus Pharmaceuticals IPO is up to ₹47.69 Cr. The final issue price of Hemant Surgical Industries IPO is ₹90.00 per share and of Remus Pharmaceuticals IPO is ₹1,229.00 per share.
Hemant Surgical Industries IPO | Remus Pharmaceuticals IPO | |
---|---|---|
Face Value | ₹10 per share | ₹10 per share |
Issue Price (Lower) | ₹85.00 per share | ₹1,150.00 per share |
Issue Price (Upper) | ₹90.00 per share | ₹1,229.00 per share |
Issue Price (Final) | ₹90.00 per share | ₹1,229.00 per share |
Discount (Retail) | ||
Discount (Employee) | ||
Market Lot Size | 1600 shares | 100 shares |
Fresh Issue Size | 27,60,000 shares | 3,88,000 shares |
Fresh Issue Size (Amount) | up to ₹24.84 Cr | up to ₹47.69 Cr |
OFS Issue Size | ||
OFS Issue Size (Amount) | ||
Issue Size Total | 27,60,000 shares | 3,88,000 shares |
Issue Size Total (Amount) | up to ₹24.84 Cr | up to ₹47.69 Cr |
Hemant Surgical Industries IPO opens on May 24, 2023, while Remus Pharmaceuticals IPO opens on May 17, 2023. The closing date of Hemant Surgical Industries IPO and Remus Pharmaceuticals IPO is May 26, 2023, and May 19, 2023, respectively.
Hemant Surgical Industries IPO | Remus Pharmaceuticals IPO | |
---|---|---|
Anchor Bid Date | May 23, 2023 | May 16, 2023 |
Issue Open | May 24, 2023 | May 17, 2023 |
Issue Close | May 26, 2023 | May 19, 2023 |
Basis Of Allotment (Tentative) | May 31, 2023 | May 24, 2023 |
Initiation of Refunds (Tentative) | Jun 01, 2023 | May 25, 2023 |
Credit of Share (Tentative) | Jun 02, 2023 | May 26, 2023 |
Listing date (Tentative) | Jun 05, 2023 | May 29, 2023 |
Anchor Lockin End date 1 | Jun 30, 2023 | Jun 23, 2023 |
Anchor Lockin End date 2 | Aug 29, 2023 | Aug 22, 2023 |
Hemant Surgical Industries IPO P/E ratio is 12.28, as compared to Remus Pharmaceuticals IPO P/E ratio of 21.09.
Hemant Surgical Industries IPO | Remus Pharmaceuticals IPO | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Financial |
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Promoter Shareholding (Pre-Issue) | 100.00% | 92.82% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Promoter Shareholding (Post-Issue) | 73.56% | 68.37% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
P/E Ratio | 12.28 | 21.09 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Market Cap | ₹93.96 Cr. | ₹181.03 Cr. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ROE | 32.42%% | 71.44%% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ROCE | 37.98%% | 69.99%% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt/Equity | 0.3 | 0.03 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
EPS | ₹10.26 | ₹33.86 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
RoNW | 32.42%% | 52.64%% |
In the Hemant Surgical Industries IPO retail investors (RII) are offered 9,16,800 shares while in Remus Pharmaceuticals IPO retail investors are offered 9,16,800 shares. Qualified institutional buyers (QIB) are offered 5,23,200 shares in Hemant Surgical Industries IPO and 1,38,750 shares in Remus Pharmaceuticals IPO.
Hemant Surgical Industries IPO | Remus Pharmaceuticals IPO | |
---|---|---|
Anchor Investor Reserveration | 7,82,400 shares | 1,10,500 shares |
Market Maker Reserveration | 1,44,000 shares | 19,500 shares |
QIB | 5,23,200 shares | 1,38,750 shares |
NII | 3,93,600 shares | 41,625 shares |
RII | 9,16,800 shares | 97,125 shares |
Employee | 0 shares | 0 shares |
Others | ||
Total | 18,33,600 shares | 2,77,500 shares |
Hemant Surgical Industries IPO subscribed 150.59x in total, whereas Remus Pharmaceuticals IPO subscribed 57.21x.
Hemant Surgical Industries IPO | Remus Pharmaceuticals IPO | |
---|---|---|
QIB (times) | 41.05x | 10.75x |
NII (times) | 277.26x | 229.31x |
Big NII (times) | ||
Small NII (times) | ||
RII (times) | 158.73x | 49.81x |
Employee (times) | ||
Other (times) | ||
Total (times) | 150.59x | 57.21x |
Add a public comment...
FREE Intraday Trading (Eq, F&O)
Flat ₹20 Per Trade in F&O
|